Search

Your search keyword '"Carlyn Tan"' showing total 3 results
Start Over Author "Carlyn Tan" Publisher wiley
3 results on '"Carlyn Tan"'

1. P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY

Author

Carlyn Tan, Emma Searle, Sébastien Anguille, Manisha Bhutani, Noa Biran, Kevin Boyd, Andrew Cowan, Jeffrey Matous, Aurore Perrot, Jesus Berdeja, Wojciech Janowski, Rakesh Popat, Hang Quach, Mark Schroeder, Sandy W Wong, Deeksha Vishwamitra, Yue Guo, Zhuolu Niu, Julie Larsen, Lingling Chen, Arnob Banerjee, and Cyrille Touzeau

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

2. P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.

Author

Ross Firestone, Tala Shekarkhand, Dhwani Patel, Malin Hultcrantz, Alexander Lesokhin, Sham Mailankody, Hani Hassoun, Carlyn Tan, Urvi Shah, Neha Korde, Kylee Maclachlan, Heather Landau, David Chung, Gunjan Shah, Sergio Giralt, Oscar Lahoud, and Saad Usmani

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

3. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis

Author

Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Sydney Lu, Dhwani Patel, Tim J Peterson, Neha Korde, Carlyn Tan, Katrina M Piedra, Urvi A Shah, Alexander M. Lesokhin, Jennifer S. Orozco, Andriy Derkach, and Cy Wilkins

Subjects
Male, Oncology, medicine.medical_specialty, Dexamethasone, Article, Bortezomib, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lenalidomide, Multiple myeloma, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Aspirin, Rivaroxaban, business.industry, Incidence, Disease Management, Retrospective cohort study, Venous Thromboembolism, Hematology, Middle Aged, medicine.disease, Carfilzomib, chemistry, Female, Disease Susceptibility, Neoplasm Grading, Multiple Myeloma, business, Oligopeptides, medicine.drug
Abstract

Incidence of venous thromboembolism (VTE) varies across different regimens in newly diagnosed multiple myeloma (NDMM) patients. Limited data exist on the use of direct oral anticoagulants as thromboprophylaxis in the setting of haematologic malignancies, specifically multiple myeloma. In this retrospective study of 305 NDMM patients, VTE rates in those treated with carfilzomib, lenalidomide, dexamethasone (KRD) + aspirin (ASA), bortezomib, lenalidomide, dexamethasone (RVD) + ASA, and KRD + rivaroxaban were statistically significant, 16·1%, 4·8%, and 4·8%, respectively. The findings confirm a higher incidence of VTE when using KRD induction compared to RVD induction and reveal that the use of low-dose rivaroxaban thromboprophylaxis can mitigate this risk without an observable increase in bleeding rates.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results